GSK Moves Closer To Priority Review Voucher As US Panel Backs Malaria Drug Tafenoquine

GlaxoSmithKline's user fee date is July 22, four days before advisory committee review of 60 Degrees’ separate application for the compound.

FDA Advisory Committee Feature image

A US FDA advisory committee’s overwhelming endorsement of the efficacy and safety of GlaxoSmithKline PLC’s Krintafel (tafenoquine) for prevention of malaria relapse positions the company to nab a tropical disease priority review voucher by the application’s July 22 user fee deadline.

On July 12, the Antimicrobial Drugs Advisory Committee voted 13-0 that GSK provided substantial evidence tafenoquine is effective for the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers